|
|
|
|
| LEADER |
04178nma a2201033 u 4500 |
| 001 |
EB001991766 |
| 003 |
EBX01000000000000001154668 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a books978-3-03936-089-5
|
| 020 |
|
|
|a 9783039360895
|
| 020 |
|
|
|a 9783039360888
|
| 100 |
1 |
|
|a Čipak Gašparović, Ana
|
| 245 |
0 |
0 |
|a Free Radical Research in Cancer
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2020
|
| 300 |
|
|
|a 1 electronic resource (192 p.)
|
| 653 |
|
|
|a antioxidant
|
| 653 |
|
|
|a nitric oxide
|
| 653 |
|
|
|a myelodysplastic syndromes
|
| 653 |
|
|
|a lapachone
|
| 653 |
|
|
|a methotrexate
|
| 653 |
|
|
|a new therapeutic strategies
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a antioxidants
|
| 653 |
|
|
|a chemoresistance
|
| 653 |
|
|
|a androgen receptor (AR), AR-V7
|
| 653 |
|
|
|a cisplatin
|
| 653 |
|
|
|a mitochondria
|
| 653 |
|
|
|a NQO1*2
|
| 653 |
|
|
|a breast cancer stem cells
|
| 653 |
|
|
|a cancer chemotherapy
|
| 653 |
|
|
|a quinone
|
| 653 |
|
|
|a 5-Fluorouracil
|
| 653 |
|
|
|a oxaliplatin
|
| 653 |
|
|
|a photodynamic therapy
|
| 653 |
|
|
|a Technology: general issues / bicssc
|
| 653 |
|
|
|a NRF2
|
| 653 |
|
|
|a ozone therapy
|
| 653 |
|
|
|a light
|
| 653 |
|
|
|a doxorubicin
|
| 653 |
|
|
|a bardoxolone methyl
|
| 653 |
|
|
|a ovary
|
| 653 |
|
|
|a prostate cancer
|
| 653 |
|
|
|a therapy resistance
|
| 653 |
|
|
|a singlet oxygen
|
| 653 |
|
|
|a breast cancer
|
| 653 |
|
|
|a reactive oxygen species
|
| 653 |
|
|
|a androgen deprivation therapy
|
| 653 |
|
|
|a granulosa cell tumor
|
| 653 |
|
|
|a Trolox
|
| 653 |
|
|
|a ayurveda
|
| 653 |
|
|
|a bleomycin
|
| 653 |
|
|
|a carbonylation
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a free radicals
|
| 653 |
|
|
|a lung cancer
|
| 653 |
|
|
|a cancer treatment
|
| 653 |
|
|
|a anti-androgen
|
| 653 |
|
|
|a menadione
|
| 653 |
|
|
|a sperm
|
| 653 |
|
|
|a extracellular matrix
|
| 653 |
|
|
|a combination therapy
|
| 653 |
|
|
|a 4-hydroxy-2-nonenal
|
| 653 |
|
|
|a antioxidant therapy
|
| 653 |
|
|
|a polymorphism
|
| 653 |
|
|
|a chemotherapy-induced toxicity
|
| 653 |
|
|
|a oxidative stress
|
| 653 |
|
|
|a triphala
|
| 653 |
|
|
|a reactive oxygen species (ROS)
|
| 653 |
|
|
|a calcium channel
|
| 653 |
|
|
|a antioxidant proteins
|
| 653 |
|
|
|a NQO1
|
| 653 |
|
|
|a cell death
|
| 653 |
|
|
|a ascorbate
|
| 653 |
|
|
|a castration-resistant prostate cancer
|
| 653 |
|
|
|a deferasirox
|
| 653 |
|
|
|a cancer metabolism
|
| 653 |
|
|
|a enzalutamide
|
| 653 |
|
|
|a chemoprevention and chemotherapy
|
| 700 |
1 |
|
|a Čipak Gašparović, Ana
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-03936-089-5
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/68644
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/2406
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 600
|
| 520 |
|
|
|a Cancer is a great challenge to efficient therapy due to biological diversity. Disturbed oxidative homeostasis in cancer cells certainly contributes to differential therapy response. Further, one of the hallmarks of cancer cells is adaptation which includes fine tuning of the cellular metabolic and signalling pathways as well as transcription profiles. There are several factors which contribute to the tumor diversity and therapy response, and oxidative stress is certainly one of them. Changes in oxygen levels due to hypoxia/reoxygenation during tumor growth modulate antioxidative patterns finally supporting increased cell diversity and adaptation to stressing conditions. Additionally, cancer chemotherapy based on ROS production can also induce also adaptation. To counteract these negative effects natural products are often used for their antioxidant activities as well as photodynamic therapy supported by novel chemosensitizers. Understanding of possible pathways which can trigger antioxidant defence at a certain time during cancer development can also provide possible strategies in fighting cancer.
|